Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms

Table 2

In vivo antibacterial effect of ebselen.

Microorganism	Strain	Model/inoculation	Dose/route of administration	Reference
E. faecium	HM-952	C57BL/6 mice/oral inoculation	10 mg/kg/oral administration	[58]
C. difficile	630	Swiss Webster mice/oral gavage	100 mg/kg/oral administration	[60]
S. aureus	Clinical	Sprague Dawley rats/skin infection	25 mg/kg/intradermal administration	[55]
A. baumanii	Clinical	Kunming mice urinary tract infection	25 mg/kg Ebs plus 6 mg/kg Ag^+/intraperitoneal administration	[62]
Y. pseudotuberculosis	Yp III	Kunming mice gastroenteritis/intragastric gavage	20 mg/kg Ebs plus 5 mg/kg Ag^+/intraperitoneal administration	[63]
S. aureus	MRSA USA300	Obese and diabetic TALLYHO/JngJ mice/infections of pressure ulcers	2%/topical administration	[57]
S. aureus	MRSA USA300	Caenorhabditis elegans AU37 (L4-stage worms)	8 μg/mL/immersion in 96-well plates	[52]
S. aureus	MRSA USA300	BALB/c mice skin infection/intradermal inoculation	1-2%/topical administration	[16]
E. coli	BC1 (UPEC)	BALB/c mice cystitis/bladders infected via transurethral catheterization	5 mg/kg Ebs plus 6 mg/kg Ag^+/intraperitoneal administration	[64]
E. coli	ZY-1 (MDR)	Kunming mice peritonitis/intraperitoneal injection	25 mg/kg Ebs plus 6 mg/kg Ag^+/intraperitoneal administration	[65]
S. aureus	MRSA USA200	BALB/c mice peritonitis/intraperitoneal injection	30 mg/kg/intraperitoneal administration	[53]

MDR: multidrug resistant; MRSA: methicillin-resistant Staphylococcus aureus; UPEC: uropathogenic E. coli.